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Apo (apolipoprotein) CIII was first isolated and character-ized nearly 50 years ago by Brown et al.1 Soon after, it 
was shown that apo CIII was an inhibitor of LpL (lipoprotein 
lipase),2 an action opposing the activity of another apoprotein; 
apo CII, the necessary activator of LpL.3 The role of apo CIII in 
lipoprotein metabolism was later expanded by studies in per-
fused rat livers demonstrating that apo CIII inhibits uptake of 
triglyceride (TG) rich lipoproteins and remnants.4,5 The identi-
fication of 2 sisters with complete absence of apo CIII because 
of a homozygous chromosomal deletion that also included apo 
AI, apo AIV, and apo AV,6 allowed us to demonstrate, in vivo, 
that absence of apo CIII resulted in a dramatic increase in li-
polysis of VLDL (very-low-density lipoprotein)-TG.7 Studies 
in mice overexpressing apo CIII or with targeted deletions of 
the APOC3 gene confirmed the human findings and also sup-
ported the role of apo CIII as an inhibitor of hepatic uptake of 
apoB100-containing lipoproteins.8–11 In addition, mouse- and 
hepatoma-based studies suggested that apo CIII may increase 
the incorporation of TG into nascent VLDL particles.10,12
Although interest in apo CIII’s role in lipid metabolism has 
continued, enthusiasm for apo CIII as a therapeutic target was 
limited by uncertainty about the relationship between hyper-
triglyceridemia and risk for cardiovascular disease (CVD).13,14 
Recent genetic studies using both genome-wide association 
and Mendelian randomization approaches have, however, es-
tablished the relationship between loss of function of apo CIII, 
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Objective—Apo (apolipoprotein) CIII inhibits lipoprotein lipase (LpL)-mediated lipolysis of VLDL (very-low-density 
lipoprotein) triglyceride (TG) and decreases hepatic uptake of VLDL remnants. The discovery that 5% of Lancaster Old 
Order Amish are heterozygous for the APOC3 R19X null mutation provided the opportunity to determine the effects of a 
naturally occurring reduction in apo CIII levels on the metabolism of atherogenic containing lipoproteins.
Approach and Results—We conducted stable isotope studies of VLDL-TG and apoB100 in 5 individuals heterozygous 
for the null mutation APOC3 R19X (CT) and their unaffected (CC) siblings. Fractional clearance rates and production 
rates of VLDL-TG and apoB100 in VLDL, IDL (intermediate-density lipoprotein), LDL, apo CIII, and apo CII were 
determined. Affected (CT) individuals had 49% reduction in plasma apo CIII levels compared with CCs (P<0.01) and 
reduced plasma levels of TG (35%, P<0.02), VLDL-TG (45%, P<0.02), and VLDL-apoB100 (36%, P<0.05). These 
changes were because of higher fractional clearance rates of VLDL-TG and VLDL-apoB100 with no differences in 
production rates. CTs had higher rates of the conversion of VLDL remnants to LDL compared with CCs. In contrast, rates 
of direct removal of VLDL remnants did not differ between the groups. As a result, the flux of apoB100 from VLDL to 
LDL was not reduced, and the plasma levels of LDL-cholesterol and LDL-apoB100 were not lower in the CT group. Apo 
CIII production rate was lower in CTs compared with CCs, whereas apo CII production rate was not different between 
the 2 groups. The fractional clearance rates of both apo CIII and apo CII were higher in CTs than CCs.
Conclusions—These studies demonstrate that 50% reductions in plasma apo CIII, in otherwise healthy subjects, results in a 
significantly higher rate of conversion of VLDL to LDL, with little effect on direct hepatic uptake of VLDL. When put in 
the context of studies demonstrating significant protection from cardiovascular events in individuals with loss of function 
variants in the APOC3 gene, our results provide strong evidence that therapies which increase the efficiency of conversion 
of VLDL to LDL, thereby reducing remnant concentrations, should reduce the risk of cardiovascular disease.
Visual Overview—An online visual overview is available for this article.  (Arterioscler Thromb Vasc Biol. 2019;39:63-72. 
DOI: 10.1161/ATVBAHA.118.311476.)
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which results in lower plasma TG concentration, and reduced 
CVD risk.15,16 We found that 5% of the Lancaster Old Order 
Amish are heterozygous carriers of a null mutation, R19X 
(HGVS NM 000040.2 c.55C>T p.Arg19Ter rs76353204) in 
the APOC3 gene, which converts an arginine to a termination 
codon, resulting in a 50% reduction of plasma apo CIII lev-
els.17 In addition to having lower fasting and postprandial TG, 
higher levels of HDL (high-density lipoprotein)-cholesterol, 
and lower levels of LDL (low-density lipoprotein)-cholesterol, 
heterozygous deficient individuals have less subclinical ath-
erosclerosis, as determined by coronary artery calcification.17 
Our report was followed by large cohort studies of APOC3 loss 
of function mutations, including R19X, which demonstrated a 
40% reduction in myocardial infarction in carriers.18,19
Based on the nonhuman mechanistic studies described 
above, heterozygous loss of function of APOC3 might reduce 
risk for CVD by any or all of the following: (1) reducing se-
cretion of VLDL from the liver, (2) increasing hepatic uptake 
of VLDL and chylomicron remnants by the liver, and (3) 
increasing lipolytic conversion of VLDL to LDL. We used 
stable isotope tracers to determine which of these 3 possible 
results of heterozygous loss of function of APOC3 would 
be most important in determining the differences in plasma 
lipids between R19X affected Amish and their unaffected 
siblings. Our findings support the development of therapies 
that lower plasma apo CIII levels as a means of treating mod-
erate to severe hypertriglyceridemia20,21 which may reduce 
risk for CVD.
Materials Methods
The data that support the findings of this study are available within 
the article and its online-only Data Supplement.
Study Subjects
We recruited 5 participants heterozygous for the APOC3 R19X muta-
tion, hereafter denoted by CT, and 5 sex-matched, unaffected siblings, 
hereafter denoted by CC, ages 35 to 71 years, from the Lancaster 
Old Order Amish population.17 Participants were not receiving lipid-
altering medications. All study participants provided written in-
formed consent and the studies were approved by the Institutional 
Review Boards of the University of Maryland School of Medicine 
and Columbia University Medical Center.
Stable Isotope Kinetic Studies
The 2 sibs, in each pair, were studied on the same day at the Amish 
Research Clinic in Lancaster, PA. The protocol for these studies was 
one that we have used previously,22 with minor modifications to allow 
subjects to complete some visits in their homes. On day 1, partici-
pants fasted for 12 hours, after which a nurse visited their homes and 
drew baseline bloods for safety and fasting lipid and lipoprotein mea-
surements. After 6 pm on day 1, they were NPO (nothing per mouth 
[oral]) until 11 pm when they started a liquid, isocaloric, 18% fat diet 
that was provided every 2 hours for the next 30 hours. At 5:30 am 
(day 2), they arrived at the Amish Research Clinic, where 2 intrave-
nous were placed in antecubital veins of each arm and baseline bloods 
were drawn (time 0 hour). Immediately after, boluses of 2H₃-L-
leucine (10 µmol/kg BW), Ring-13C₆-L-phenylalanine (29.4 µmol/kg 
BW), and 2H₅-glycerol (100 µmol/kg BW) were administered over a 
10-minute period, followed by a constant infusion of 2H₃-L-leucine 
(10 µmol/kg BW per hour) over 15 hours. Additional blood samples 
were collected at 20 and 40 minutes, and at 1, 2, 4, 6, 8, 10, 12, 14, 15, 
15.2, 15.4, 16 hours after the administration of tracers and processed 
to isolate plasma and serum. After the 16 hours blood sample, the 
subjects returned to their homes where they continued to consume the 
liquid meal protocol. Eight hours later a nurse drew the final 24 hours 
blood sample in their homes. VLDL, IDL (intermediate-density lipo-
protein), LDL, and HDL were obtained from the 16 plasma samples 
via sequential density ultracentrifugation.
Determination of Stable Isotope 
Enrichment of ApoB100 and TG
The isolated lipoprotein fractions were used to determine stable iso-
topic enrichments of 2H₃-L-leucine and Ring-13C₆-L-phenylalanine 
in apoB100 in VLDL, IDL, and LDL. ApoB100 was isolated from 
VLDL, IDL, and LDL by SDS-polyacrylamide gel electrophoresis. 
The isolated apoB100 bands were excised from the gels, hydrolyzed, 
and the amino acids derivatized. Plasma free amino acids were recov-
ered from 0.25 mL plasma after precipitation of proteins with ace-
tone and extraction of the aqueous phase with hexane. The aqueous 






in apoB100-lipoproteins and plasma free leucine and phenylalanine 
were measured by gas chromatography-mass spectrometer using an 
Agilent 6890 gas chromatography and a 5973 mass spectrometer 
with negative chemical ionization. Additionally, kinetic analysis of 
TG in VLDL was performed with 2H₅-glycerol. TG was separated 
from phospholipid by zeolite binding. The TG was resolubilize with 
chloroform. We performed transesterfication with methanolic HCL. 
Glycerol was isolated by liquid/liquid extraction (hexane and water 
added) and derivatized to triacetin (glycerol triacetate) through in-
cubation with acetic anhydride. We performed gas chromatography-
mass spectrometer positive chemical ionization with selective ion 
monitoring of m/z 159 and 164.
Compartmental Modeling of 
ApoB100 and TG Metabolism
Fractional clearance rates (FCRs) and production rates (PR) of TG 
and apoB100 in VLDL, and of apoB100 in IDL and LDL were de-
termined using a compartmental model to fit stable isotope enrich-
ment data.23–25 In our general model, apoB100 and TG are required 
to have the same pool structure and the same rate constants for each 
VLDL pool, but with different mass distributions. With >1 pool in 
the VLDL fraction, the different mass distributions lead to different 
VLDL-FCRs for TG and apoB, since VLDL-FCR is obtained as a 
weighted average of the individual FCRs (the weights given by the 
mass distribution). However, if there is only one pool in the VLDL 
fraction, TG and apoB necessarily have the same FCR. For each 
study, the minimum number of pools needed to simultaneously fit 
the 9 sets of data (2 tracers, leucine and phenylalanine, in VLDL-, 
IDL-, and LDL-apoB100 and plasma amino acids, and 1 tracer, glyc-
erol, in VLDL-TG) is chosen for the final model. In the present study, 
the final model had 1 pool each for VLDL, IDL, and LDL. The data 
were fitted by least squares, giving equal weight to all data points 
(ie, assuming a constant error variance for all measurements) using a 
computer program, Pool fit,23 which solves the differential equations 
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in closed form and computes the fits and parameter sensitivities as 
sums of exponentials. The fits yielded fractional clearance rates 
(FCRs) of apoB100 in VLDL, IDL, and LDL, and TG in VLDL. 
The model also estimated rates of conversion of apoB100 between 
VLDL, IDL, and LDL. PRs (mg/kg per day) were calculated by 
multiplying FCRs (in pools/day) by the appropriate lipoprotein pool 
sizes of apoB100, which were calculated as each lipoprotein’s con-
centration of apoB100 in mg/dL multiplied by an estimate of each 
individual’s plasma volume (45 mL/kg). Schematics of the models 
used to analyze apoB100, TG-glycerol, and apo CIII in the present 
study are included in the supplement (Figure I in the online-only 
Data Supplement). Based on the best fit of the present data, we have 
only one VLDL pool for apoB and TG, direct conversion of VLDL-
apoB to LDL, as well as conversion from VLDL to LDL via IDL, 
no direct out pathway from IDL, and a small component of direct 
secretion of LDL from the liver.
Determination of Stable Isotope 
Enrichment of Apo CII and Apo CIII
Apo CIII enrichment with 2H₃-L-leucine was measured using 
Ultraperformance liquid chromatography-mass spectrometry. 
VLDL and HDL fractions were digested with trypsin as previously 
described.26 A multiple reaction monitoring method was used to de-
termine the following precursor-product ion transitions for a pep-
tide specific to apo CIII (GWVTDGFSSLK; M0: 599.0>854.5; M3: 
600.5>857.6) and apo CII (TYLPAVDEK; M0: 518.4>658.4; M3: 
519.9>658.4).
Compartmental Modeling of Apo 
CII and Apo CIII Metabolism
The 2H
3
-leucine enrichment data for apo CII and apo CIII in HDL or 
VLDL was fitted by a single pool with the VLDL-apoB100 enrich-
ment plateau used as the best available estimate of the liver leucine 
pool enrichment. Separate FCRs were estimated for HDL and VLDL. 
While the enrichment of apo CIII was different between HDL and 
VLDL, there was a constant ratio across time-points in any single 
study. This means that the FCR of apo CIII is estimated to be the 
same in VLDL and HDL; any difference is solely because of random 
measurement error. We ascribe this to apo CIII moving freely among 
lipoproteins.27 The situation was similar with apo CII. Therefore, we a 
calculated single plasma FCR for apo CIII and apo CII. Apo CIII and 
apo CII PRs were calculated using the FCR for each apolipoprotein 
and its plasma pool size, as described above for apoB.
Quantitation of Apo CIII in VLDL and HDL Fractions
Apo CIII was quantitated by Ultraperformance liquid chromatogra-
phy-mass spectrometry, using a Waters Xevo TQS triple quad mass 
spectrometer coupled with an Acquity UPLC (Waters, Milford, MA). 
VLDL and HDL fractions were digested with trypsin as described 
previously.28 In brief, 200 μL of ultracentrifuged VLDL or HDL 
from each time-point was desalted, reduced with dithiothreitol, 
alkylated with iodoacetamide, and digested with trypsin overnight. 
A multiple reaction monitoring method was used to determine the 
following precursor-product ion transitions for a peptide specific to 
apo CIII (GWVTDGFSSLK; M0: 599.0>854.5) and a deuterated 
internal standard (M8: 603.0>862.5). Lower limit of quantitation, 
defined as the level at which the residual of the calibration line is 
<20% of the expected concentration was determined to be 1 nm. The 
intra-assay precision for the assay was 4.00%. Apo CII was similarly 
quantitated using the following precursor-product ion transitions for 
a peptide specific to apo CII (TYLPAVDEK; M0: 518.4>658.4; M3: 
519.9>658.4). The proportions of plasma apo CIII and apo CII resid-
ing in VLDL and HDL were then calculated.
Biochemical and Immunologic Assays
Day 1 blood was collected after a 12-hour overnight fasting period. 
Additional timed blood samples were collected while the subjects 
were consuming the liquid diet, both before (0 hour) and at various 
time-points after the stable isotope infusion was started (20 and 40 
minutes, 1, 2, 4, 6, 8, 10, 12, 14, 15, 15.2, 15.4, 16, and 24 hours.). 
Plasma cholesterol, TG, and HDL cholesterol were measured by 
Integra400plus (Roche). Plasma LDL-cholesterol levels were esti-
mated using the Friedewald formula. Cholesterol and TG were also 
measured enzymatically in VLDL, IDL, LDL, and HDL isolated by 
ultracentrifugation. Plasma apo CII, apo CIII, and apoE were meas-
ured by human ELISA kits (ab168549 [apo CII]; ab154131 [apo CIII]; 
ab108813 [apoE], Abcam, Cambridge, MA). ApoB100 in plasma and 
in VLDL, IDL, and LDL was measured using an apoB100 ELISA kit 
(A70102 AlerCheck, Inc).
Statistical Analysis
The data are presented as means and SD. The mutation effects 
were assessed by analyzing within-pair differences for statis-
tical significance using paired t tests. The primary end point 
was the percent difference in FCR of VLDL-TG and VLDL-
apoB100 between affected and unaffected sib-pairs, and 
P=0.05 was considered significant. A key secondary end point 
was the partition of VLDL between conversion to LDL and 
hepatic uptake, and P=0.01 was considered significant. All 
other comparisons were exploratory.
Results
Study Population
We enrolled 10 participants (5 CT and 5 CC), including 
3 affected males, 2 affected females, and sex- and age- 
(within 10 years) matched unaffected siblings. Mean ages 
(CT 50±11.1, CC 52.4±12.4) and body mass index (CT 
28.6±4.3, CC 26.9±5.9) were similar between the groups 
(Table1).
Plasma Lipid and Apolipoprotein Levels
Plasma TG levels were lower in the CT subjects (61±29 mg/
dL) versus their CC siblings (92±26 mg/dL; Table 1). The 
mean (±SD) percent difference for TG between the pairs was 
35±20 (P<0.02). Total plasma cholesterol levels did not dif-
fer between sib-pairs. Although we have previously shown 
that APOC3 R19X carriers have higher HDL and lower LDL-
cholesterol levels,17 in this much smaller sample, the levels 
of cholesterol in these lipoproteins were not significantly dif-
ferent between the pairs. Plasma levels of apoB100 and apoE 
were not different between the 2 groups, but, as expected, apo 
CIII levels were significantly reduced in the CT group (CT 
61±18 µg/mL versus CC 123±33 µg/mL) with a mean per-
cent difference between pairs of 49±19 (P<0.01). Of interest, 
apo CII levels were also lower in the affected (48±23 µg/mL) 
compared with the unaffected siblings (71±25 µg/mL), with 
a mean percent difference of 35±14 (P<0.01). The percent of 
plasma apo CIII in VLDL was similar in the CT (23±9%) and 
CC (28±9%) groups. The percent of plasma apo CII in VLDL 
was also similar in the CT (30±14%) and CC (35±10%) 
groups.
The cholesterol and TG levels in the isolated VLDL frac-
tions (Table 2) were lower in the CT (4±2.0 mg/dL and 18±12 
mg/dL, respectively) than in their CC siblings(7±3 mg/dL 
and 32±11 mg/dL, respectively; P<0.03 for cholesterol and 
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and LDL fractions were not different between the sib-pairs. 
Despite similar plasma apoB100 levels, VLDL-apoB100 lev-
els were lower in the CT (2±0.5 mg/dL) compared with the 
CC (4±2 mg/dL), with a mean percent difference between 
pairs of 36±48 (P<0.05). There were no differences in IDL- or 
LDL-apoB100 levels between the sib-pairs.
ApoB100 and TG Metabolism
As noted in Methods, we modeled VLDL-TG and VLDL-
apoB100 metabolism jointly, and the best fits of the stable 
isotope enrichment data required only a single VLDL pool. 
Thus, the VLDL-apoB100 FCR and VLDL-TG FCR in each 
subject were the same. The results demonstrate that the lower 
levels of VLDL-TG and VLDL-apoB100 in the CT group 
were because of a significantly greater FCR of VLDL-TG and 
VLDL-apoB100 (% increase 116±31, P<0.001; Table 3). The 
VLDL-apoB100 PRs were similar in the CT and CC siblings 
(27±7 and 26±12 mg/kg per day, respectively), as were the 
VLDL-TG PRs (790±291 and 555±156 mg/kg per day). The 
ratio of VLDL-TG PR to VLDL-apoB
 
 PR, an indicator of the 
size of newly secreted VLDL particles, did not differ between 
the groups (CT 32±13 versus CC 27±19).
We also found that the FCR of IDL-apoB100 was greater 
in the CT individuals compared with their CC siblings (% in-
crease 203±223; P<0.02). We did not observe differences be-
tween sib-pairs in the FCR of LDL-apoB100 or in the PRs of 
IDL- or LDL-apoB100. There were 3 sources of LDL-apoB: 
conversion of VLDL to LDL via IDL, direct conversion of 
VLDL to LDL, and direct secretion of LDL from the liver. 
These made up, respectively on the average, 31%, 62%, and 
7% of LDL-PR in the CT siblings and 33%, 55%, and 12% in 
the CC siblings; none of the sources differed significantly be-
tween the groups (Table 3).
A key secondary goal of the study was to determine the 
effects of reduced apo CIII levels on the partitioning of VLDL-
apoB100 flux between conversion of VLDL to LDL and direct 










VLDL-Chol 6.9±3.4 3.5±1.9 −47.9±13.3*
IDL-Chol 3.07±2.9 1.47±1.0 −37.3±35.8
LDL-Chol 61.7±24.0 56.6±13.6 −4.1±22.7
VLDL-TG 31.6±11.0 17.7±11.7 −45.3±26.6*
IDL-TG 3.12±2.0 1.89±1.1 −36.1±24.5
LDL-TG 9.6±3.8 8.6±2.2 −6.1±26.0
VLDL-apoB100 4.29±2.1 2.0±0.47 −36.4±47.6*
IDL-apoB100 1.96±1.9 1.07±0.66 −24.6±41.7
LDL-apoB100 51.2±15.3 58.0±22.6 −13.6±32.9
Participants are defined as CC (unaffected siblings) and CT (affected siblings). 
Data were obtained from 5 time-points during the 24-h period of the stable 
isotope studies. Data are presented as means and SD of absolute concentrations 
as well as the means and SDs of the percent differences between CC and CT 
groups. Statistical significance of the percent differences was assessed using 
paired t tests. ApoB100, apolipoprotein B100; chol, cholesterol; TG, triglycerides; 
VLDL, very-low-density lipoprotein; IDL, intermediate-density lipoprotein; and 
LDL, low-density lipoprotein.
*Significant at P<0.05.
Table 1. Baseline Characteristics and Plasma Lipid and Apolipoprotein Levels of APOC3 R19X Carriers and Unaffected Sib-Pairs











CC1 F 55 34 181 62 92 78 105 140 45 52
CC2 F 71 18 167 120 100 44 70 138 94 223
CC3 M 53 26 303 117 219 60 142 85 101 172
CC4 M 37 30 179 88 98 63 66.2 160 63 236
CC5 M 48 27 137 73 84 39 66 92 53 94
Mean±SD  52±12 27±6 193±64 92±26 119±56 57±16 90±34 123±33 71±25 155±81
CT1 F 46 27 145 25 76 63 53 30 22 165
CT2 F 63 32 215 103 127 68 87 75 73 160
CT3 M 50 34 220 67 138 69 120 69 70 154
CT4 M 35 28 160 61 92 57 64 63 45 164
CT5 M 57 23 173 48 93 70 105 66 28 92
Mean±SD  50±11 29±4 183±33 61±29 105±26 65±5 86±28 61±18 48±23 147±31
%Difference 
(SD)
 −2.3 (22.1) 13.7 (40.9) −1.6 (20.8) −35.2 (20.1)* −4.9 (±22.9) 22.3 (34) −2.6 (17.2) −49.1 (18.5)† −35.1 (13.8)† 17.0 (55.5)
Participants are defined as CC (unaffected siblings) and CT (affected siblings), in order of sib-pairs. All lipid and lipoprotein levels were obtained from 5 time-points 
during the 24-h period of the stable isotope studies. Data are presented as means and SD of absolute concentrations as well as means and SD of the percent differences 
between the 2 groups. Statistical significance of the percent differences was assessed using paired t tests. Apo indicates plasma apolipoprotein; BMI, body mass index; 
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removal of VLDL by the liver. The Figure depicts a model 
of apoB100-lipoprotein transport from the liver to circulating 
VLDL, and then to either LDL or back to the liver. Inherent 
to this model is the concept that the initial LpL-mediated li-
polysis of VLDL-TG generates a smaller particle with less TG 
than present at the time of secretion into the circulation, and 
at some point in this process, the particle has lost enough TG 
that it has a density >1.006 and, therefore, leaves the VLDL 
pool. This particle can be found in the IDL and LDL pools 
or be irreversibly taken up by the liver. It is important to un-
derstand that although we show a single VLDL pool in the 
Figure, it comprises a range of VLDL of differing size and 
number of TG molecules: the largest and most TG-rich VLDL 
are those that have just entered the circulating VLDL pool and 
the smallest and most TG-poor are those that have undergone 
lipolysis and are about to either leave the circulation directly 
or become IDL or LDL. We show a single pool, despite the 
heterogeneous nature of the population of VLDL within this 
pool, because when we used a model with >1 VLDL pool, it 
did not improve the fit of our kinetic data. As noted above, the 
rates of secretion of newly synthesized VLDL from the liver 
(equal to VLDL-PR) were similar for CT and CC siblings 
and, therefore, the blue arrows from the liver to VLDL in each 
group are the same. However, because lipolysis of VLDL-TG 
was much faster in the CTs (depicted by the much thicker 
black arrow coming out from VLDL in that group), the size of 
the VLDL pool in CTs was about 36% smaller than the VLDL 
pool of CCs (Table 2). The green and red arrows represent 
the number of VLDL plasma pools each day that, after lipol-
ysis of TG, move either to LDL or to the liver, respectively. 
Our compartmental analysis indicated that there was a sig-
nificant 12.3±6.3 pools/day difference in the FCRs between 
CT and CC sib-pairs for the conversion of VLDL-apoB100 
to IDL and LDL (P=0.01), but only a 3.6±7.3 pools/d differ-
ence in FCRs between the 2 groups for direct hepatic removal 
of those particles (P=0.33). Thus, only the conversion rate of 
VLDL to LDL, for example, the lipolytic pathway, was sig-
nificantly greater in the group with partial loss of apo CIII. 
This is depicted by the thicker green arrow in CT compared 
with CC, whereas the red arrows are similar in the 2 groups 
(Figure). The individual and mean data for these parameters 
are presented in Table 4. This greater rate of conversion of 
VLDL to IDL and LDL versus uptake by the liver was re-
flected by a nonsignificant increase in LDL-apoB100 PR in 
the CT compared with the CC group (Table 3).
As noted above, the generation of LDL from VLDL 
occurred via direct conversion of VLDL to LDL or conversion 
of VLDL to IDL followed by conversion of the latter to LDL, 
with direct conversion accounting for the largest proportion 
of LDL generated. We were able, using our model, to deter-
mine the FCRs of each of these pathways in the CT and CC 
groups, and these data are presented in Table 4. The FCR for 
direct conversion of VLDL to LDL was significantly greater 
(14.8±9.1 pools/d) in the CT siblings than in the CC group 
(5.5±5.7 pools/d; P=0.04). There was no difference in the 
FCRs for conversion of VLDL to LDL via IDL between the 
2 groups (CT: 6.5±4.0; CC: 3.5±4.6 pools/d; P=0.2). These 
results, together with those for the FCRs of overall conver-
sion to LDL versus direct uptake of VLDL, support much 
greater lipolytic activity in the affected versus the nonaffected 
sib-pairs.
Apo CIII and Apo CII Metabolism
Previous studies by several groups have demonstrated that the 
kinetics of rapidly exchangeable apolipoproteins such as apo 
CIII and apo CII29 can only be characterized by plasma FCRs 
and PRs.30–32 However, because of a lack of unanimity on this 
issue,33 we determined enrichments of each apolipoprotein in 
both VLDL and HDL, which together transport nearly all of 
these 2 proteins in plasma. We found essentially identical FCRs 
for both apo CIII and apo CII in VLDL and HDL (Table I in the 
online-only Data Supplement) and, therefore, have presented 
only a single FCR and PR for each apolipoprotein in Table 5. 
In the CC group, the FCRs of apo CIII (1.3±0.7 pools/d) and 
apo CII (1.4±0.8 pools/d) were similar, consistent with a com-
mon clearance pathway of each of these apolipoproteins.34On 
the other hand, the PR of apo CIII (7.4±6 mg/kg per day) was 
almost double that of apo CII (3.9±2 mg/kg per day), indicative 
of unique regulation of the synthesis of these 2 apolipopro-
teins. Similar differences in the PRs of apo CIII and apo CII 
have been reported previously.34 In the CT group, the FCRs of 
Table 3. Effects of APOC3 R19X Mutation on Kinetic Parameters for TG and 
ApoB100 Metabolism
 CC±SD CT±SD % Difference±SD
VLDL-TG and VLDL-apoB100 
FCR, pools/d
15.0±6.0 31.0±8.9 116±31*
IDL-apoB100 FCR, pools/d 5.9±3.1 12.2±2.6 203±223†
LDL-apoB100 FCR, pools/d 0.63±0.31 0.77±0.18 37±43




IDL-apoB100 PR, mg/kg 
per d
4.0±3.1 5.6±3.5 122±222
LDL-apoB100 PR, mg/kg 
per day
14.8±8.7 19.1±5.6 58±72
LDL-apoB PR from VLDL via 
IDL, mg/kg per d
4.0±3.1 5.6±3.5  
LDL-apoB PR directly from 
VLDL, mg/kg per d
8.4±9.8 11.9±4.8  
LDL-apoB PR from the liver, 
mg/kg per d




Participants are defined as CC (unaffected siblings) and CT (affected 
siblings). Data derived from compartmental modeling of stable isotope 
enrichment of samples obtained over a 24 h. period. Data are presented as 
means and SD of the absolute FCRs and PRs as well as the means and SD 
of the percent difference in each parameter between the CT and CC groups. 
Statistical significance of the percent differences was assessed using paired t 
tests. ApoB indicates apolipoprotein B100; FCR, fractional clearance rate; IDL, 
intermediate-density lipoprotein; LDL, low-density lipoprotein; PR: production 
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apo CIII (1.8±0.5 pools/d) and apo CII (2.3±0.9 pool/d) were 
also similar but, in contrast to the CC group, the PRs of apo 
CIII (4.9±1.7 mg/kg per day) and apo CII (4.2±1.2 mg/kg per 
day) in the CT group were also similar, reflecting the reduced 
rate of synthesis of apo CIII in the CT versus the CC subjects, 
resulting from the APOC3 R19X null mutation. For both apo 
CIII and apo CII, neither the FCR nor the PR was significantly 
different between the CT and CC subjects.
Discussion
We used stable isotopes to investigate, in vivo, the effects of 
heterozygosity for the APOC3 R19X null mutation and the 
associated 50% lower levels of plasma apo CIII on apoB100 
and TG metabolism. Our purpose was to determine the rela-
tive importance of haplodeficiency for 3 proposed physiolog-
ical roles of apo CIII in VLDL metabolism: (1) inhibition of 
LpL-mediated lipolysis of VLDL-TG, (2) inhibition of hepatic 
uptake of VLDL or TG-rich remnant particles, and (3) stimula-
tion of the incorporation of TG into VLDL in the liver. Each of 
these roles, which have been demonstrated by in vitro assays or 
by studies in cells and mouse models, could have a significant 
impact on the efficacy of therapeutic agents that partially in-
hibit apo CIII synthesis for treatment of hypertriglyceridemia 
and for prevention of CVD. The most significant differences 
we observed between affected CT and unaffected CC sib-pairs 
were the higher in FCRs for VLDL-TG and VLDL-apoB100 
in the CT. The 50% lower circulating apo CIII levels in the 
R19X carriers resulted from the doubling of the rate of clear-
ance of TG-rich apoB100-lipoproteins from the bloodstream. 
The clearance of VLDL occurs as a 2-stage process. First, LpL 
hydrolyzes the TG in nascent VLDL as these particles circu-
late through the vascular beds of adipose tissue and muscle,35 
generating what is typically designated as a remnant that still 
contains less TG, but enough to keep its density <1.006 (within 
the VLDL range). These particles circulate back to the liver, 
which is believed to be the site of the second stage. The latter 
actually has 2 components; 1 comprises additional lipolysis of 
remnant TG by LpL, and probably more importantly hepatic 
lipase, resulting in conversion of VLDL to IDL and LDL.36 
The second component involves interaction of apoB100 with 
one or more receptors and proteoglycans on the cell surface of 
the liver, resulting in internalization of the remnant particle.37–39 
Importantly, it is not clear whether these are completely in-
dependent parallel pathways or if some additional lipolysis 
is necessary before remnant uptake by the liver occurs. Our 
kinetic data do not allow us to differentiate between these 
possibilities and, therefore, we have made them independent, 
parallel pathways.
Our compartmental modeling of stable isotope enrich-
ments of TG and apoB100 in VLDL, and of apoB100 in IDL 
and LDL, enabled us to determine the effect of partial loss 
of apo CIII on each of the second stage pathways. Indeed, 
our results indicate that the rates of conversion of VLDL 
particles to LDL were significantly greater in the carriers of 
R19X. The findings that the FCR of IDL-apoB100 (which 
was not removed directly) was also significantly greater in 
the CT group supports higher rates of conversion of VLDL 
to LDL, as does a nonsignificant, numerical increase in the 
PR of LDL-apoB100. All of the present results are in accord 
with those from our previous study in 2 sisters with complete 
loss of apo CIII because of a large homozygous chromo-
somal deletion, where we demonstrated marked increases in 
FCRs of VLDL-apoB100 and VLDL-TG as well as normal or 
increased rates of conversion of VLDL-apoB100 to LDL.7 In 
Figure. The figures depict the effects of partial loss of apo CIII (apolipoprotein CIII) synthesis of the metabolism of VLDL (very-low-density lipoprotein). Although 
the rates of secretion of VLDL-apoB100 and VLDL triglyceride (TG; blue arrows) are similar in CC (unaffected siblings) and CT (affected siblings), the size of the 
VLDL plasma pool (blue circles) is reduced by 36% in CT because an increase in LpL (lipoprotein lipase) mediated lipolysis of VLDL-TG (black arrows) leads 
to a doubling of the fraction clearance rate of apoB100 and TG from the VLDL pool. The lipolysis of VLDL-TG generates particles that either undergo conver-
sion to IDL (intermediate-density lipoprotein) and LDL (green arrows) after additional lipolysis of TG by LpL or hepatic lipase or direct removal by the liver (red 
arrows). The rate of conversion of VLDL to LDL was significantly greater in CT compared with CC whereas the rates of direct removal were similar in the 2 
groups (Table 4). These data indicate that, in individuals heterozygous for loss of function of APOC3, who have normal levels of lipoprotein lipase, reduced lev-




 http://ahajournals.org by on February 3, 2020
Reyes-Soffer et al  Effects of Apo C3 Mutation on Lipid Metabolism  69
the present study, we did not find a significant effect of partial 
loss of apo CIII synthesis on the uptake of VLDL remnants by 
the liver. This result might seem to conflict with results of re-
cent studies of the efficacy of an apo CIII antisense in patients 
with no LpL, where the significant reductions in plasma TG 
levels observed would have required increased direct removal 
of TG-rich lipoproteins, presumably by the liver.40 However, 
whereas hepatic removal of TG-rich lipoproteins was the only 
pathway that would be susceptible for inhibition by apo CIII 
in patients lacking LpL, our participants would have both of 
the apo CIII-susceptible pathways available for participation 
in the metabolism of VLDL. A simple explanation for our 
results might be that more efficient LpL-mediated lipolysis 
of nascent VLDL resulted in smaller VLDL that were more 
depleted of TG than post-lipolysis VLDL in nonaffected indi-
viduals and, therefore, more likely to be converted to IDL 
and LDL by additional lipolytic activities during the second 
stage of VLDL metabolism than to be internalized by LDL 
family receptor-mediated pathways present in the liver.38,39 
Our results also contrast with recent studies of the effects of 
apo CIII antisense in mice with targeted deletion of LpL, LDL 
receptors, the LDL receptor-related protein-1, and heparin 
sulfate proteoglycan receptors.41 Their results led the authors 
to conclude that apo CIII inhibited hepatic uptake of remnant 
lipoproteins, but had little or no effect on LpL-mediated li-
polysis of TG. Although those studies were convincing, they 
were in mice, where apoB48-apoE enriched lipoproteins are 
predominant, and where hepatic removal of remnants is much 
greater than in humans. Direct comparisons between the 2 
studies are, therefore, very limited.
In contrast to the significant effect of reduced apo CIII on 
clearance of VLDL-TG and VLDL-apoB100, we did not find 
any evidence supporting a role for apo CIII in the incorporation 
of TG into nascent VLDL within the liver.10,12 Our result agrees 
with data showing that treatment of apo CIII transgenic mice 
with an apo CIII antisense had no effect on rates of VLDL secre-
tion,42 and with our previous finding of normal VLDL-apoB100 
and VLDL-TG PRs in the 2 patients with complete absence of 
apo CIII.7 Our results, indicating that partial loss of apo CIII has 
a significant impact on the lipolytic pathway but not on direct re-
moval of VLDL remnants, raise obvious questions about the po-
tential of therapies that lower apo CIII levels. On the one hand, it 
is clear that the marked increase in VLDL-TG FCR is consistent 






ApoB100 to LDL  
FCR, pools/d
Conversion of VLDL-
ApoB100 to LDL Directly 
FCR, pools/d
Conversion of VLDL-
ApoB100 to LDL Via IDL 
FCR, pools/d
Direct Removal of 
VLDL-ApoB100  
FCR, pools/d
CC1 18.7 18.7 7.24 11.42 0.00
CC2 7.82 2.15 1.64 0.51 5.67
CC3 10.1 3.73 0.9 2.83 6.32
CC4 22.4 15.2 14.66 0.57 7.16
CC5 16.1 4.98 3.04 1.94 11.1
Mean±SD 15.0±6.0 9.0±7.5 5.5±5.7 3.5±4.6 6.05±3.98
CT1 37.8 37.8 28.43 9.32 0.00
CT2 20.5 11.9 5.22 6.7 8.56
CT3 22.8 22.8 11.41 11.41 0.00
CT4 40.3 22.0 19.14 2.83 18.3
CT5 33.5 11.9 9.90 2.05 21.5
Mean±SD 31.0±8.87 21.3±10.6 14.8±9.1 6.5±4.0 9.67±10.0
Difference±SD 16.0±3.02† 12.3±6.28* 9.3±7.2* 3.0±4.4 3.6±7.3
Participants are defined as CC (unaffected siblings), CT (affected siblings), in order of sib-pairs. VLDL: very-low-density lipoprotein, Data derived from compartmental 
modeling of stable isotope enrichments obtained over a 24 h. period. Data are presented as means and SD of the absolute FCRs of VLDL-apoB100, the conversion of 
VLDL-apoB100, and the direct removal of VLDL-apoB100, as well as the means and SD of the absolute differences in each parameter between the CT and CC groups. 
Conversion of VLDL-apoB100 to LDL includes both conversion of VLDL directly to IDL as well as VLDL to IDL and IDL to LDL. There was no direct conversion of VLDL to 
LDL required to fit the kinetic data; all the conversion occurred through IDL. Statistical significance assessed using paired t tests. ApoB indicates apolipoprotein B100; FCR, 
fractional clearance rate; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; PR: production rate; TG, triglycerides; and VLDL, very low-density lipoprotein.
*Significant P<0.05.
†Significant P<0.001.
Table 5. Effects of APOC3 R19X Mutation on Kinetic Parameters for Apo CIII 
and Apo CII Metabolism
  CC (±SD) CT (±SD) Difference
Apo CIII FCR 1.3±0.7 1.8±0.5 0.59±0.38
PR 7.4±6 4.9±2 −2.54±4.83
Apo CII FCR 1.4±0.8 2.3±1 0.90±0.74
PR 3.9±2 4.2±1 0.33±1.34
Participants are defined as CC (unaffected siblings) and CT (affected siblings). 
Data are presented as means and SD. There were no significant differences for 
any of the variables between CC and CT groups or apo CIII and apo CII. FCR 
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with the dramatic reductions in TG levels observed in a study 
where patients with marked hypertriglyceridemia without muta-
tions in LpL were treated with an antisense to apo CIII.43 Those 
results indicate the utility of apo CIII-lowering therapy to pre-
vent pancreatitis in such patients. In contrast, if therapies that 
reduce apo CIII synthesis result in higher rates of conversion of 
VLDL remnants to LDL with no change or modest increases 
in LDL-cholesterol or apoB100 levels,43,44 how could that trans-
late to risk for CVD? Specifically, how do our findings relate 
to the decreased levels of coronary calcification in R19X car-
riers17 and very significant reductions in CVD risk observed in 
cohorts with loss of function variants in the APOC3 gene.15,16 A 
simple answer is that reducing the number of VLDL remnants, 
which carry more cholesterol per particle than LDL, is beneficial 
regardless of the mechanism involved. Individuals with dyslip-
idemia and the apo E2/2 genotype accumulate both apoB100 
and apoB48 remnants and have significantly increased risk 
for CVD.45,46 Amish individuals heterozygous for the APOC3 
R19X mutation and individuals with the combined deletion of 
APOA1/APOC3/APOA4/APOA5 had decreased postprandial TG 
levels,7,47 which have been shown to be atherogenic.48,49 More 
dramatic reductions in postprandial lipid levels were reported 
recently in a small number of individuals homozygous for the 
R19X mutation in APOC3.50 Of note, individuals in that study 
who were either heterozygotes or homozygoutes for R19X had 
LDL-cholesterol levels that were similar to noncarriers.49 A re-
cently published study comparing the roles of remnant choles-
terol versus LDL-cholesterol in reduced CVD risk in 137 895 
individuals with loss of function of APOC3 found that lower 
concentrations of remnant cholesterol accounted for nearly all of 
the benefit of lower apo CIII levels.51 Importantly, genetic stud-
ies have demonstrated that gain of function variants in the LPL 
gene are associated with reduced risk for CVD, whereas loss 
of function variants in this gene are associated with increased 
risk.52,53 Our stable isotope kinetic studies of apo CIII and apo 
CII showed the expected lower apo CIII PR in the CT compared 
with the CC group, but no difference in apo CII PR between 
affected and unaffected siblings. These results are in accord 
with the isolated R19X mutation in the CT group and indica-
tive of independent regulation of the expression of the APOC3 
and APOC2 genes which are on different chromosomes. In con-
trast, the FCRs of both apo CIII and apo CII were greater in 
the affected compared with the unaffected siblings, suggestive 
of a common pathway for the clearance of these 2 apolipopro-
teins from the plasma, possibly along with VLDL remnants. The 
FCRs of apo CIII and apo CII are greater than those of both 
LDL-apoB100 and HDL apo AI, and slower than the FCRs of 
VLDL- and IDL-apoB100. However, as both apo CIII and apo 
CII are associated with all the major lipoproteins, a model that 
has reservoirs of apo CIII and apo CII on HDL that would feed 
a catabolic pathway through VLDL remnants seems reasonable 
to explain our results. A recent article describing the effects of 
a rare mutation in APOC3 that affected the binding of the apo-
lipoprotein to lipoproteins resulted in clearance of apo CIII via 
the kidney.54 We previously demonstrated a role of the kidney 
in the catabolism of apo AI in hypertriglyceridemic individu-
als.55 While we cannot rule out involvement of the kidney in the 
increased catabolism of apo CIII and apo CII in the CT group, 
evidence for a significant pool of free apo CIII or free apo CII 
in plasma is lacking,56,57 and the mutation in APOC3 in our CT 
subjects results in decreased secretion with no evidence of al-
tered lipoprotein distribution of apo CIII synthesized by the 
normal allele. Of note, the lower levels of apo CII in the CT 
group did not seem to restrict or limit the effect of low apo CIII 
on VLDL-TG clearance. This is consistent with the lack of any 
alteration in plasma lipid levels in heterozygotes for apo CII de-
ficiency.58 Despite uncertainties about the effects on CVD risk, 
which will require large randomized, placebo-controlled CVD 
outcome trials to resolve, the very large reductions of plasma 
TG levels observed with apo CIII antisense indicate that thera-
pies to significantly lower apo CIII concentrations in the circu-
lation could add a new, potent approach for the prevention of 
pancreatitis in patients with severe hypertriglyceridemia.59 We 
also realize that other proatherogenic or proinflammatory effects 
of apo CIII have been reported, and these may also be reversed 
by therapies that reduce apo CIII levels.60,61
Study Limitations
This study included a small number of participants, a short-
coming that we attempted to alleviate by using sib-pairs. We 
also did not address the heterogeneous nature of apoB100-
lipoproteins, particularly related to the presence of apo CIII 
on only a portion of VLDL, IDL, and LDL, demonstrated 
first by Alaupovic et al62 and then in a series of stable isotope 
kinetic studies by Zheng et al,63 Mendivil et al,64 and Sacks 
et al.65 The finding that there are apoB100-lipoproteins with 
and without apo CIII could have an important implication for 
the present study. We would note, however, that Sacks et al65 
have reported that 40% to 80% of VLDL from individuals 
with normal TG levels contain 60 to 100 apo CIII molecules 
per particle. Thus, it seems likely that a 50% reduction of apo 
CIII in R19X carriers would not significantly alter the propor-
tion of VLDL that containing significant numbers of apo CIII 
molecules, and that the affected and unaffected siblings would 
have relatively similar proportions of VLDL with and without 
apo CIII. Our finding that the proportions of both apo CIII 
and apo CII in VLDL were similar in affected and unaffected 
siblings suggests similar proportions of apo CIII-containing 
VLDL in both groups. Importantly, we acknowledge that the 
metabolic differences we are reporting between affected and 
unaffected siblings may not completely mimic the effects of a 
therapeutic agent that reduces levels of plasma apo CIII.
Conclusions
The present studies demonstrate the physiological effects of 
50% reductions in plasma apo CIII resulting from heterozy-
gosity for a naturally occurring loss of function mutation in 
the APOC3 gene. Lower apo CIII levels in the circulation 
resulted in higher rates of lipolysis of VLDL-TG and higher 
rates of conversion of VLDL to LDL in the affected siblings. 
We did not observe changes in the rate of direct remnant re-
moval of VLDL remnants by the liver or in rates of secretion 
of VLDL. Our results, together with those from cohorts with 
loss of function variants in the APOCIII gene, provide evi-
dence for the increased atherogenicity of VLDL (and chylo-
micron) remnants, as well as support for therapies that would 
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involved. The impact of loss of function variants in apo CIII 
might be of particular importance in the postprandial period.
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Highlights
• APOC3 R19X null mutation causes 50% lower levels of plasma apo CIII.
• The changes in apo CIII levels were because of a doubling of the rate of clearance of TG-rich apoB100-lipoproteins from the bloodstream.
• These results provide strong evidence that therapies which increase the efficiency of conversion of VLDL to LDL, thereby reducing remnant 
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